E3 PreliminaryPreliminaryPEM unclearMethods-PaperPeer-reviewedMachine draft
A robust, single-injection method for targeted, broad-spectrum plasma metabolomics.
Li, Kefeng, Naviaux, Jane C, Bright, A Taylor et al. · Metabolomics : Official journal of the Metabolomic Society · 2017 · DOI
Quick Summary
Researchers developed a new, efficient blood test that can measure over 600 different molecules (metabolites) in a single sample to help diagnose ME/CFS. The test was validated by showing it could correctly identify ME/CFS patients with 95% accuracy compared to healthy controls, even when tested again more than a year later by different researchers.
Why It Matters
This study presents a practical, scalable metabolomic platform that could facilitate objective biological diagnosis of ME/CFS—a disease that currently lacks validated biomarkers. The method's reproducibility across time, instruments, and operators suggests it may enable multicenter research and clinical translation of metabolite-based diagnostic signatures for ME/CFS.
Observed Findings
- A single-injection LC-MS/MS method successfully measured 610 metabolites from 63 biochemical pathways with total imprecision <12% CV.
- Eight previously identified metabolite biomarkers maintained 95% diagnostic accuracy (95% CI 85-100%) for discriminating CFS from controls.
- The assay demonstrated stability and reproducibility across a 1.5-year interval, different instruments, and different operators.
- 610 metabolites plus 95 stable isotope internal standards were quantified in a 45-minute HILIC separation.
Inferred Conclusions
- A robust, single-injection targeted metabolomic platform can efficiently measure broad-spectrum plasma metabolites with acceptable analytical performance.
- Metabolite biomarkers for CFS show stability and reproducibility sufficient for potential clinical application.
- This method may serve as a useful diagnostic tool for ME/CFS and other complex diseases.
Remaining Questions
- Will this metabolite signature maintain similar diagnostic accuracy in female ME/CFS patients and in more ethnically diverse populations?
- Can these metabolite biomarkers discriminate ME/CFS from other chronic conditions with overlapping symptoms (e.g., fibromyalgia, long COVID)?
- What are the biological mechanisms linking these 8 metabolites to ME/CFS pathophysiology?
What This Study Does Not Prove
This study does not prove that these metabolite signatures cause ME/CFS or explain the underlying mechanisms of disease. It also does not establish whether this method will work in female patients, more diverse populations, or patients with other chronic illnesses, and does not validate the test's performance in blinded clinical diagnostic settings. The small sample size (22 CFS cases) limits generalizability of the diagnostic accuracy findings.
Tags
Biomarker:MetabolomicsBlood Biomarker
Method Flag:Small SampleExploratory Only
Metadata
- DOI
- 10.1007/s11306-017-1264-1
- PMID
- 28943831
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →